JoslynKirbyMD

Dermatology • Hershey, PA

Physician

Join to view full profile

Dr. Kirby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kirby's full profile

Already have an account?

Office
500 University Drive
Mail Code HU14
Hershey, PA 17033
Phone+1 717-531-8307

Education & Training

University of Virginia School of MedicineClass of 2004

Certifications & Licensure

PA State Medical License 2004 - 2024
American Board of Dermatology Dermatology

Clinical Trials

Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment Start of enrollment: 2022 Oct 13
Recruiting
Phase 2

Publications & Presentations

PubMed

24 citations
Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guideline recommendations and opportunities fo...
Chelsey E. Straight, Young H. Lee, Guodong Liu, Joslyn S. Kirby
Journal of the American Academy of Dermatology. 2015-05-01
4 citations
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
Bria Midgette, Andrew Strunk, Oleg Akilov, Afsaneh Alavi, Christine Ardon
The British Journal of Dermatology. 2022-12-01
202 citations
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Par...
Ali Alikhan, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard
Journal of the American Academy of Dermatology. 2019-07-01

Journal Articles

Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa
Joslyn S Kirby, Andrea L Zaenglein, JAMA Dermatology

Lectures

How to be an Effective Clinician Educator
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019

Press Mentions

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis SuppurativaFebruary 10th, 2023
Clinical Challenge: Managing Pain in Hidradenitis SuppurativaAugust 27th, 2021
Differences Between Children and Adults with Hidradenitis SuppurativaAugust 11th, 2021
Join now to see all